Skip to content
Review

Molecular Restoration Through Replacement Therapies: Current Advances and Future Directions in Treating Diseases

Jul 2026 · DNA and Cell Biology · Vol 45, pp. 490 - 508 · 0 citations · 213 references
Medicine

TL;DR

Different modalities, including protein replacement, gene therapy, messenger RNA (mRNA) replacement, noncoding RNA (ncRNA) therapies, cell replacement, and gene editing, aimed at addressing and treating the fundamental genetic defects underlying a range of diseases are discussed.

Abstract

Replacement therapy is an advanced therapeutic approach for diseases caused by molecular deficits. It aims to restore normal physiology by replacing deficient molecules such as enzymes, proteins, genes, or other molecules. Here, we discuss different modalities, including protein replacement, gene therapy, messenger RNA (mRNA) replacement, noncoding RNA (ncRNA) therapies, cell replacement, and gene editing, aimed at addressing and treating the fundamental genetic defects underlying a range of diseases. These therapies could have potentially curative and disease-modifying effects when used to directly replace deficient or dysfunctional components, addressing the inherent limitations of conventional therapies, such as off-target effects and control of disease-related symptoms. Some replacement therapies, such as protein therapy, gene therapy, and cell therapy, are already approved for clinical use, while emerging approaches—including mRNA therapy, ncRNA therapy, and gene editing—remain primarily in the preclinical or clinical trial stages. To achieve broad clinical translation of these emerging approaches, key challenges, including delivery, safety, specificity, and ethical concerns, must be addressed. This review provides an overview of the existing modalities of replacement therapies, their mechanisms of action, and future directions for improving clinical translation, efficacy, and accessibility.

View source

Similar papers

Open access Aug 2026

Gene therapy for rare diseases marks a new era in precision medicine: Insights from clinical trials

Clinical evidence suggests that gene-based therapies in the management of rare diseases can achieve sustained functional benefits, reduce disease-related complications, and lessen dependence on long-term replacement or supportive treatments.

S. Suprianto, Y. Messe, Raehan AH. Hamzah et al. · 0 citations
#gene editing Review Open access Sep 2026

Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms

A multidimensional framework is proposed in which gene therapy platforms are evaluated according to three intrinsic properties—genetic precision, temporal control, and dosage tunability—while delivery, clinical maturity, and disease context act as major translational constraints.

Jared Wieland, Peyton Jackson, William Penrod et al. · 0 citations
Review Open access Sep 2026

RNA therapeutics: current status and future directions

This review focuses on druggable functional RNAs and discusses current and emerging technologies, as well as the scope for their potential clinical utility and targeted treatment, and highlights the most studied optimization strategies and delivery systems designed to enhance the efficacy and tissue-specific delivery o...

Barbara Yang, Melina J. Sedano, Karla Perez et al. · 0 citations
#gene editing Review Sep 2026

CRISPR–cas systems in pharmacology: functional pharmacogenomics, drug screening, resistance, and therapeutic translation

Overall, CRISPR-Cas9 represents a vital platform for future pharmacological innovation, but its broad clinical use may require further validation of safety, efficacy, durability, and accessibility.

Muhammad Saeed Akhtar, Adnan Amin · 0 citations
Review Open access Aug 2026

Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA

This Review highlights self-amplifying RNA (saRNA) as a next-generation platform for tumor suppressor restoration and describes a translational prioritization framework to identify tumor suppressors best suited for saRNA-based replacement, with particular emphasis on cancers harboring recurrent homozygous deletions.

D. Mutha, Chaithanya P. Vedula, Sanjana Bhagavatula et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.